CrownBio’s inflammation portfolio provides well-characterized in vivo models for inflammatory and autoimmune disease drug development.
CrownBio provides a range of validated genomic and proteomic biomarker assays to inform on oncology, inflammation.
PDX models offer the most translational preclinical in vivo models for efficacy screening in oncology drug development.
As an integral step in the oncology drug discovery process, cell line derived xenografts provide data for key decision-making in a timely and cost-effective manner.
Syngeneic tumor models are a key platform for immuno-oncology research. Syngeneic are homografts derived from immortalized mouse cancer cell lines which originated from the same inbred strain of mice.
CrownBio exclusively provides preclinical oncology drug development and validation services using unique 3D organoid models developed using IP-protected Hubrecht Organoid Technology (HUB) protocols, as well as HUB’s biobank of already established patient-derived organoids (PDO).
CrownBio has developed an expansive menu of well-characterized cancer cell lines for in vitro evaluation of novel agents to help guide early stage decisions on which agents to progress.
cellPrism® is a drug development platform offering customizable cell-based in vitro assays using optimally sourced and processed primary cells (blood and bone marrow cells) from multiple species.